Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
US-ATG-F for GVHD Prevention in Allo-SCT
NCT01295710Phase 3Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Oct 2011
- Primary completion
- Oct 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of grafalon in graft-versus-host disease (GVHD), sponsored by Neovii Pharmaceuticals. Started Oct 2011; status: completed.
02
Drugs
grafalon
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01295710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295710.